Reata, Kyowa Kirin End Bardoxolone CKD Development

Missed Secondary Endpoint In Japan Trial

 
• By Lisa Takagi
Kyowa Kirin / Reata
Kyowa Kirin’s decision to withdraw from Japanese development set to impact bardoxolone’s US pathway • Source: Shutterstock

More from Japan

More from Focus On Asia